LogicBio Therapeutics (OTCMKTS:LOGC) Sees Unusually-High Trading Volume – Should You Buy?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) saw unusually-high trading volume on Thursday . Approximately 402,240 shares changed hands during trading, an increase of 189% from the previous session’s volume of 139,226 shares.The stock last traded at $14.82 and had previously closed at $14.90.

LogicBio Therapeutics Stock Performance

The stock’s 50-day moving average is $11.35 and its 200 day moving average is $9.59. The stock has a market cap of $680.01 million, a price-to-earnings ratio of -20.37 and a beta of 2.11. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $33.60 million during the quarter, compared to the consensus estimate of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.